The management of cutaneous squamous cell carcinoma (CSCC) is undergoing a notable shift, with systemic immunotherapy playing ...

Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant ...

Imaging is more sensitive than physical examination for nodal staging of cutaneous squamous cell carcinoma, according to a ...

Switching to sirolimus significantly reduces the risk of subsequent cSCC in high-risk kidney transplant recipients with history of the skin cancer. Switching kidney transplant recipients (KTRs) with ...

Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo. The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the ...

What factors may put patients at an increased risk of cutaneous squamous cell carcinoma, and what should they know about ...